Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial

杜瓦卢马布 医学 乳腺癌 肿瘤科 肿瘤微环境 放射治疗 内科学 免疫检查点 化疗 癌症 人口 新辅助治疗 免疫系统 激素疗法 泌尿科 封锁 肿块切除术 免疫疗法 临床研究阶段 转录组 放射科 癌症研究 临床试验
作者
Alex De Caluwé,Isabelle Desmoulins,Kim I. Cao,Vincent M. Remouchamps,Adinda Baten,E. Longton,Karine Peignaux,Andrea Joaquin Garcia,David Venet,Luca Arecco,Elisa Agostinetto,Guilherme Nader Marta,Zoë Denis,Jennifer Dhont,Paulus Kristanto,Xavier Catteau,Denis Larsimont,Roberto Salgado,Philip M. Poortmans,John Stagg
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:32 (7): 2461-2472 被引量:6
标识
DOI:10.1038/s41591-026-04453-z
摘要

Abstract Patients with estrogen receptor-positive (ER + ), HER2-negative, early breast cancer (BC) have low pathologic complete response (pCR) rates following neoadjuvant chemotherapy. Immune checkpoint inhibitors (ICIs) provide limited benefit in programmed death-ligand 1 (PD-L1)-negative tumors, characterized by an immune-cold tumor microenvironment. Here we hypothesized that immune-modulating stereotactic body radiation therapy (iSBRT; 3 × 8 Gy) could enhance response through tumor microenvironment reprogramming, and that CD73 blockade could further improve efficacy. We conducted a phase 2, randomized, multicenter trial (Neo-CheckRay) in 147 female patients with high-risk, ER + HER2 − early BC. Patients received neoadjuvant chemotherapy plus iSBRT alone (No_ICI), with anti-PD-L1 durvalumab (Single_ICI) or with durvalumab plus anti-CD73 oleclumab (Double_ICI). In the intention-to-treat population, the primary endpoint, residual cancer burden 0/1 rate, was 35.4% with No_ICI, 45.1% with Single_ICI and 47.9% with Double_ICI, without statistically significant differences. pCR rates were 16.7%, 29.4% and 33.3%, respectively ( P = 0.059). In the per-protocol population (MammaPrint High Risk, n = 131), pCR rates were 16.3%, 32.6% and 35.6%, respectively ( P = 0.040). Among PD-L1-negative tumors ( n = 91), pCR rates were 3.4%, 28.1% and 30.0%, respectively. No new safety signals were observed. Baseline transcriptomic analysis showed low immune signature expression in PD-L1-negative tumors. Paired baseline and on-treatment biopsies obtained 1 week after iSBRT demonstrated tumor microenvironment reprogramming toward an inflamed phenotype in the iSBRT + anti-PD-L1 arms. These findings suggest that iSBRT + anti-PD-L1 may convert immune-cold ER + HER2 − BC into more inflamed tumors and improve response, particularly in PD-L1-negative disease. ClinicalTrials.gov registration: NCT03875573 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
茫123456完成签到,获得积分10
1秒前
小潘潘发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
skyler完成签到,获得积分10
3秒前
3秒前
小二郎的应助被corleeang采纳,获得10
3秒前
3秒前
3秒前
4秒前
poker21发布了新的文献求助10
4秒前
4秒前
九霄发布了新的文献求助10
4秒前
钟梓袄发布了新的文献求助10
4秒前
LUCKY发布了新的文献求助10
4秒前
聪慧易巧发布了新的文献求助10
5秒前
5秒前
研友_8yNO0L发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
bkagyin的应助被Elcric采纳,获得10
6秒前
粉红小板凳完成签到,获得积分10
6秒前
7秒前
1111完成签到,获得积分10
7秒前
7秒前
FashionBoy的应助被难得糊涂采纳,获得10
7秒前
传奇3的应助被Linnet采纳,获得30
7秒前
7秒前
Moon发布了新的文献求助10
7秒前
初霜猫尾发布了新的文献求助10
7秒前
Akim的应助被会飞的鱼采纳,获得10
7秒前
lb发布了新的文献求助10
7秒前
7秒前
7秒前
8秒前
打打的应助被Eana采纳,获得10
8秒前
8秒前
小小完成签到,获得积分20
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046